Entecavir plus tenofovir combination therapy in patients with multidrug‐resistant chronic hepatitis B: results of a multicentre, prospective study

• DOI: 10.1111/liv.13059
• Publication Date: 2016-01-19T13:27:08Z
• Authors: Jun Yong Park; Chang Wook Kim; Si Hyun Bae; Kyu Sik Jung; Hee Yeon Kim; Seung Kew Yoon; Kwang‐Hyub Han; Sang Hoon Ahn
• Keywords: Entecavir; Tenofovir; Hepatitis B

Abstract Background & Aims Sequential therapy posed a high risk of emergence multidrug resistance and presented management issue in chronic hepatitis B ( CHB ) treatment. We evaluated the antiviral efficacy safety entecavir ETV plus tenofovir TDF combination multidrug‐resistant MDR patients. Methods In this prospective, multicentre study, patients, defined as measurable serum HBV DNA (≥60 IU/ml) while on any rescue treatment regimen for at least 24 weeks presence documented prior genotypic to both nucleoside analogue(s) nucleotide analogue, were treated with 1.0 mg 300 48 weeks. Results A total 64 eligible patients who had previously failed median three lines (range, 2–6) included. At baseline, age was 47.0 years, 89.1% HB eAg(+), 4.24 2.11–6.73) log 10 IU/ml. By week 4, 12, 48, 15/64 (23.4%), 36/64 (56.3%), 43/64 (67.2%) 55/64 (85.9%) achieved <60 IU/ml respectively. The mean reduction from baseline 4 1.23 2.38 Although five experienced virological breakthrough, all transient no resistant mutation or novel detected Conclusions difficult‐to‐treat exposure multiple drugs, can provide very rate viral suppression through